{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,9,16]],"date-time":"2024-09-16T08:00:09Z","timestamp":1726473609806},"reference-count":9,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2014,2,1]],"date-time":"2014-02-01T00:00:00Z","timestamp":1391212800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica"],"published-print":{"date-parts":[[2014,2]]},"DOI":"10.1016\/j.eimc.2013.08.002","type":"journal-article","created":{"date-parts":[[2013,10,19]],"date-time":"2013-10-19T00:15:33Z","timestamp":1382141733000},"page":"93-95","source":"Crossref","is-referenced-by-count":1,"title":["Tratamiento antirretroviral de inicio en pacientes infectados por el virus de la inmunodeficiencia humana en Espa\u00f1a: decisiones con relaci\u00f3n a caracter\u00edsticas inmunovirol\u00f3gicas espec\u00edficas (estudio PERFIL-es)"],"prefix":"10.1016","volume":"32","author":[{"given":"Pompeyo","family":"Viciana","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Ocampo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Henar","family":"Hevia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marta","family":"Palazuelos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francisco","family":"Ledesma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.eimc.2013.08.002_bib0005","unstructured":"Gu\u00edas de tratamiento antirretroviral DHHS (2012). Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents [actualizado Mar 2012]. Disponible en: http:\/\/aidsinfo.nih.gov\/Guidelines\/HTML\/1\/adult-and-adolescent-treatment-guidelines\/0"},{"key":"10.1016\/j.eimc.2013.08.002_bib0010","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.eimc.2012.03.006","article-title":"Documento de consenso de Gesida\/Plan Nacional sobre el Sida respecto al tratamiento antirretroviral en adultos infectados por el virus de la inmunodeficiencia humana (actualizaci\u00f3n enero de 2012)","volume":"30","year":"2012","journal-title":"Enferm Infecc Microbiol Clin"},{"key":"10.1016\/j.eimc.2013.08.002_bib0015","unstructured":"European AIDS Clinical Society (EACS) Guidelines: Clinical management of treatment of HIV infected adults in Europe. Disponible en: http:\/\/www.europeanaidsclinicalsociety.org\/images\/stories\/EACS-Pdf\/EACSGuidelines-v6.1-Spanish.pdf [consultado Nov 2012]."},{"key":"10.1016\/j.eimc.2013.08.002_bib0020","first-page":"215","article-title":"First-line boosted protease inhibitor-based regimens in treatment-naive HIV-1-infected patients--making a good thing better","volume":"11","author":"Llibre","year":"2009","journal-title":"AIDS Rev"},{"key":"10.1016\/j.eimc.2013.08.002_bib0025","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1097\/QAD.0b013e32832d7350","article-title":"Once-daily darunavir\/ritonavir vs lopinavir\/ritonavir in treatment-naive, HIV-1-infected patients: 96-week analysis","volume":"23","author":"Mills","year":"2009","journal-title":"AIDS"},{"key":"10.1016\/j.eimc.2013.08.002_bib0030","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/S0140-6736(08)61081-8","article-title":"Once-daily atazanavir\/ritonavir versus twice-daily lopinavir\/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study","volume":"372","author":"Molina","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.eimc.2013.08.002_bib0035","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1093\/jac\/dkn121","article-title":"First-line antiretroviral therapy with efavirenz or lopinavir\/ritonavir plus two nucleoside analogues: The SUSKA study, a non-randomized comparison from the VACH cohort","volume":"61","author":"Domingo","year":"2008","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.eimc.2013.08.002_bib0040","first-page":"40","article-title":"[An\u00e1lisis del tratamiento antirretroviral inicial en pacientes VIH]","volume":"28","author":"Perez","year":"2004","journal-title":"Farm Hosp"},{"key":"10.1016\/j.eimc.2013.08.002_bib0045","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1157\/13096749","article-title":"[Spanish cohort of naive HIV-infected patients (CoRIS): Rationale, organization and initial results]","volume":"25","author":"Caro-Murillo","year":"2007","journal-title":"Enferm Infecc Microbiol Clin"}],"container-title":["Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0213005X13002449?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0213005X13002449?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,10,12]],"date-time":"2018-10-12T01:22:23Z","timestamp":1539307343000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0213005X13002449"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,2]]},"references-count":9,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2014,2]]}},"alternative-id":["S0213005X13002449"],"URL":"https:\/\/doi.org\/10.1016\/j.eimc.2013.08.002","relation":{},"ISSN":["0213-005X"],"issn-type":[{"type":"print","value":"0213-005X"}],"subject":[],"published":{"date-parts":[[2014,2]]}}}